NDAINHALATIONAEROSOL, METERED
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
INTAL (cromolyn sodium) by Pfizer is clinical pharmacology: in vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. First approved in 1985.
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTAL (cromolyn sodium) is a mast cell stabilizer inhaled as a metered aerosol that prevents the release of histamine and leukotrienes from mast cells. It is used primarily for the prophylaxis of asthma and allergic rhinitis. The drug has no intrinsic vasoconstrictor, antihistamine, or glucocorticoid activity and works exclusively through mast cell membrane stabilization.
LOE Approaching
Declining
With LOE approaching and competitive pressure at 30%, the commercial team is likely consolidating and optimizing portfolio allocation toward newer inhaled therapies.
Mechanism of Action
CLINICAL PHARMACOLOGY: In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Cromolyn sodium acts by inhibiting the release of histamine and leukotrienes (SRS-A) from the mast cell. Cromolyn sodium has no intrinsic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INTAL offers limited career advancement due to its LOE-approaching lifecycle and declining market relevance; roles are typically focused on revenue preservation and product maintenance rather than growth. Pharma professionals assigned to this product should view it as a consolidation or optimization role and seek lateral movement to growth-stage brands for career progression.
Worked on INTAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.